09:21 AM EST - Oncolytics Biotech Inc. : Announced preclinical data demonstrating the synergistic anti-leukemic effects of pelareorep combined with the chemotherapeutic agent azacitidine. The data were featured in a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, which took place from December 11-14, 2021, in Atlanta, Georgia. Preclinical studies featured in the poster evaluated pelareorep in combination with azacitidine in acute myeloid leukemia cells in vitro and in a leukemia xenograft mouse model. Oncolytics Biotech Inc.
shares T.ONC are trading down 0.01 cent at $2.02.
